Table 1.
Characteristics of the included patients.
| Characteristics | |
|---|---|
| No. of patients | 126 |
| Age, mean (SD) [range], years | 48.3 (9.3) [21–66] |
| Male, n (%) | 81 (64.3) |
| BMI, mean (SD) [range], kg/m2 | 24.2 (2.9) [17.7–36.2] |
| AST, median (IQR) [range], IU/l | 31.0 (24.0–47.5) [14.0–376.0] |
| ALT, median (IQR) [range], IU/l | 41.0 (25.0–67.5) [8.0–362.0] |
| ALP, median (IQR) [range], IU/l | 72.0 (62.0–91.6) [37.0–406.0] |
| GGT, median (IQR) [range], IU/l | 33.0 (21.00–73.0) [11.0–412.0] |
| Total bilirubin, median (IQR) [range], umol/l | 13.9 (10.6–20.1) [4.2–187.5] |
| Serum albumin, mean (SD) [range], g/l | 41.5 (4.1) [23.0–49.6] |
| Platelets count, mean (SD) [range], 109/l | 186.5 (52.5) [94.0–311.0] |
| Prothrombin activity, mean (SD) [range], % | 98.4 (13.5) [68.0–142.0] |
| METAVIR fibrosis stage, n (%) | |
| F0 | 12 (9.5%) |
| F1 | 38 (30.2%) |
| F2 | 42 (33.3%) |
| F3 | 14 (11.1%) |
| F4 | 20 (15.9%) |